Novartis Faces $3 Billion MS Opportunity and Key Risks

NeuroSense Therapeutics said it received a letter from Nasdaq's Listing Qualifications Department on October 1, 2026, stating the company has not regained compliance with Listing Rule 5550(b)(2), which requires a minimum market value of listed securities of $35 million for continued listing on the Nasdaq Capital Market. The company intends to appeal the Staff Determination by timely requesting a hearing before the Nasdaq Hearings Panel and to seek additional time to regain compliance with the MVLS Requirement, which is the only continued listing criterion identified in the determination. Nasdaq had notified NeuroSense on April 2, 2026, that its MVLS had been below $35 million for 30 consecutive trading days, giving it until September 29, 2026, to regain compliance; because it did not, its ordinary shares and warrants face delisting unless it appeals. A timely hearing request stays the suspension of the company's securities and the filing of a Form 25-NSE with the SEC pending the Panel's decision, and the Panel has discretion to grant an exception of up to 180 days from the date of the Staff Determination. Separately, NeuroSense said Nasdaq confirmed it regained compliance with Listing Rule 5550(a)(2), the $1.00 minimum bid price requirement, after its 1-for-20 reverse share split kept the closing bid price at $1.00 or greater for 10 consecutive business days from September 15 through September 28, 2026, closing that matter. Chief Executive Officer Alon Ben-Noon said regaining bid price compliance is an important step and that the company remains focused on advancing PrimeC in ALS, including preparations for its Phase 3 PARAGON trial and a planned New Drug Submission to Health Canada.